ATE366809T1 - Addressine der schleimhaut und der blutgefässe und ihre verwendung - Google Patents

Addressine der schleimhaut und der blutgefässe und ihre verwendung

Info

Publication number
ATE366809T1
ATE366809T1 AT96906504T AT96906504T ATE366809T1 AT E366809 T1 ATE366809 T1 AT E366809T1 AT 96906504 T AT96906504 T AT 96906504T AT 96906504 T AT96906504 T AT 96906504T AT E366809 T1 ATE366809 T1 AT E366809T1
Authority
AT
Austria
Prior art keywords
madcam
primate
recombinant
proteins
relates
Prior art date
Application number
AT96906504T
Other languages
English (en)
Inventor
Michael J Briskin
Douglas J Ringler
Dominic Picarella
Walter Newman
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27011628&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE366809(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/386,857 external-priority patent/US6551593B1/en
Priority claimed from US08/523,004 external-priority patent/US7750137B2/en
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Application granted granted Critical
Publication of ATE366809T1 publication Critical patent/ATE366809T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • External Artificial Organs (AREA)
AT96906504T 1995-02-10 1996-02-12 Addressine der schleimhaut und der blutgefässe und ihre verwendung ATE366809T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/386,857 US6551593B1 (en) 1995-02-10 1995-02-10 Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US08/523,004 US7750137B2 (en) 1995-09-01 1995-09-01 Mucosal vascular addressins

Publications (1)

Publication Number Publication Date
ATE366809T1 true ATE366809T1 (de) 2007-08-15

Family

ID=27011628

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96906504T ATE366809T1 (de) 1995-02-10 1996-02-12 Addressine der schleimhaut und der blutgefässe und ihre verwendung

Country Status (12)

Country Link
EP (1) EP0808367B1 (de)
JP (1) JP4205162B2 (de)
AT (1) ATE366809T1 (de)
AU (1) AU4986296A (de)
CA (1) CA2212702C (de)
DE (1) DE69637155T2 (de)
DK (1) DK0808367T3 (de)
ES (1) ES2290955T3 (de)
MX (1) MX9706049A (de)
NZ (1) NZ303523A (de)
PT (1) PT808367E (de)
WO (1) WO1996024673A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0948597A4 (de) * 1996-11-01 2002-07-10 Human Genome Sciences Inc Menschliches, Schleimhaut-spezifisches Addressin-Zelladhäsionsmolekül (MAdCAM-1) und dessen Spleissvarianten
AU7348798A (en) * 1997-05-09 1998-12-08 John P. Robarts Research Institute, The Method for dislodging infiltrated leukocytes from a tissue
WO1999058573A1 (en) * 1998-05-13 1999-11-18 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AU2007201698B2 (en) * 1998-05-13 2011-10-13 Genentech, Inc. Diagnosis and treatment of hepatic disorders
US7090845B2 (en) 1998-05-13 2006-08-15 Genentech, Inc. Diagnosis and treatment of hepatic disorders
AUPR524101A0 (en) 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
WO2003047526A2 (en) * 2001-11-30 2003-06-12 Incyte Genomics, Inc. Cell adhesion and extracellular matrix proteins
US20070202097A1 (en) * 2003-03-10 2007-08-30 Krissansen Geoffrey W Monoclonal Antibodies That Recognise Mucosal Addressin Cell Adhesion Molecule-1 (Madcam-1), Soluble Madcam-1 And Uses Thereof
DE602004030565D1 (de) * 2003-05-01 2011-01-27 Scripps Research Inst Selektive r-cadherin-antagonisten und verfahren
MX370489B (es) * 2004-01-09 2019-12-16 Pfizer Anticuerpos contra madcam.
WO2006026759A2 (en) 2004-09-03 2006-03-09 Genentech, Inc. Humanized anti-beta7 antagonists and uses therefor
EP1904531B1 (de) * 2005-07-08 2010-10-06 Pfizer Limited Madcam-antikörper
WO2007007152A2 (en) * 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
KR101361905B1 (ko) * 2008-05-16 2014-02-21 제넨테크, 인크. 베타7 인테그린 길항제를 이용한 위장관 염증 장애의 치료를 평가하기 위한 바이오마커의 용도
MX367097B (es) 2011-05-02 2019-08-05 Millennium Pharm Inc FORMULACION PARA ANTICUERPO ANTI-A4ß7.
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
WO2016086147A1 (en) 2014-11-26 2016-06-02 Millennium Pharmaceuticals, Inc. Vedolizumab for the treatment of fistulizing crohn's disease
WO2016105572A1 (en) 2014-12-24 2016-06-30 Millennium Pharmaceuticals, Inc. PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY
MA41636A (fr) 2015-03-06 2018-01-09 Millennium Pharm Inc Méthode de traitement de la cholangite sclérosante primitive
AU2017234010B2 (en) 2016-03-14 2024-06-13 Millennium Pharmaceuticals, Inc. Methods of treating or preventing graft versus host disease
CA3017743A1 (en) 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
JP7069032B2 (ja) 2016-03-24 2022-05-17 ミレニアム ファーマシューティカルズ, インコーポレイテッド がん免疫治療における胃腸の免疫関連有害事象の治療方法
WO2017165742A1 (en) 2016-03-24 2017-09-28 Millennium Pharmaceuticals, Inc. Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments
US10918716B2 (en) 2016-05-04 2021-02-16 Millennium Pharmaceuticals, Inc. Triple combination therapy for treating Crohn's disease
EP3468597A1 (de) 2016-06-12 2019-04-17 Millennium Pharmaceuticals, Inc. Verfahren zur behandlung von entzündlicher darmerkrankung
WO2018104893A1 (en) 2016-12-06 2018-06-14 Glaxosmithkline Intellectual Property Development Limited Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life
AU2018256840A1 (en) 2017-04-28 2019-11-07 Millennium Pharmaceuticals, Inc. Method of treating pediatric disorders with antibodies specific for alpha 4 beta 7 integrin (vedolizumab)
EP3652211A1 (de) 2017-07-14 2020-05-20 Pfizer Inc. Antikörper gegen madcam
BR112021023345A2 (pt) * 2019-05-20 2022-02-01 Pandion Operations Inc Imunotolerância com alvo em madcam
WO2024249568A1 (en) 2023-05-30 2024-12-05 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
WO2024252368A2 (en) 2023-06-09 2024-12-12 Takeda Pharmaceutical Company Limited Methods and compositions for treating ulcerative colitis
CN121889424A (zh) 2023-08-14 2026-04-17 派拉冈医疗公司 α4β7整联蛋白结合蛋白及使用方法
WO2026058045A1 (en) 2024-09-12 2026-03-19 Takeda Pharmaceutical Company Limited Alpha4beta7 inhibitor and il-23 inhibitor combination therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5675794A (en) * 1992-12-15 1994-07-04 Board Of Trustees Of The Leland Stanford Junior University Mucosal vascular addressin, dna and expression

Also Published As

Publication number Publication date
DE69637155T2 (de) 2008-02-07
WO1996024673A1 (en) 1996-08-15
DK0808367T3 (da) 2007-11-05
JP4205162B2 (ja) 2009-01-07
AU4986296A (en) 1996-08-27
JPH10513365A (ja) 1998-12-22
ES2290955T3 (es) 2008-02-16
CA2212702A1 (en) 1996-08-15
EP0808367A1 (de) 1997-11-26
PT808367E (pt) 2007-10-22
CA2212702C (en) 2010-04-20
MX9706049A (es) 1998-02-28
DE69637155D1 (de) 2007-08-23
EP0808367B1 (de) 2007-07-11
NZ303523A (en) 2002-02-01

Similar Documents

Publication Publication Date Title
ATE366809T1 (de) Addressine der schleimhaut und der blutgefässe und ihre verwendung
Geiser et al. The interleukin-8-related chemotactic cytokines GRO alpha, GRO beta, and GRO gamma activate human neutrophil and basophil leukocytes
ES2063350T5 (es) Nuevas proteinas con efecto inhibidor del tnf y su obtencion.
Wuyts et al. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties
CA2073045C (en) A human t cell reactive feline protein (trfp) isolated from house dust and uses therefor
DE60219611T2 (de) Modifizierte annexin-proteine und verhinderung und behandlung von thrombose
KR101151805B1 (ko) 바이포달 펩타이드 바인더
US20060173162A1 (en) Bactericidak anti-apoptotic, pro-inflammatory and anti-inflammatory peptides of heparin-binding protein (hbp)
JP2742925B2 (ja) 血栓形成抑制用治療薬組成物
Kokot et al. Tamm-Horsfall protein updated
WO1996022371A3 (en) C-C CHEMOKINE RECEPTOR 3: CKP-3 OR Eos-L2
KR970002917B1 (ko) 인터루킨-i 억제제
JPH03204896A (ja) インターフェロンレセプター細胞外断片
EP0616615B1 (de) Analoge des menschlichen Interleukin-8.
EA009414B1 (ru) Терапевтические применения вариантов хемокинов
Campistol et al. Polymerization of normal and intact β2-microglobulin as the amyloidogenic protein in dialysis-amyloidosis
KR0150000B1 (ko) 사람 macif 활성을 지닌 단백질을 암호화하는 유전자, 이 유전자를 함유하는 발현 벡터, 형질전환 세포 및 사람 macif 활성을 갖는 단백질
EP1683866B1 (de) Deletionsmutanten des IgE-abhängigen Histamin-Releasing-Faktor (HRF) mit der Fähigkeit zur Histaminfreisetzung, HRF-bindende Peptide sowie deren Verwendung
CN111848780A (zh) 一种IL-36的可溶性受体sIL-36R及其应用
EP0698666B1 (de) Modifiziertes Epimorphin
JP3103531B2 (ja) ヒト尿由来細胞接着糖蛋白質及びその製造方法
Deyl et al. Collagen αA and αB chains constitute two separate molecular species
EP0612349B1 (de) Neues thrombininhibitorisches protein aus raubwanzen
CA2310677C (en) In vitro and in vivo growth-promoting proteins and peptides for kidney epithelial cells
JP3647473B2 (ja) 個別性をもつ癌細胞を特徴づけるのに有用な、癌の治療的、予防的、診断的薬剤